Skip to main content
. Author manuscript; available in PMC: 2011 Mar 29.
Published in final edited form as: Ann Thorac Cardiovasc Surg. 2009 Aug;15(4):213–220.

Table 1.

Immunotherapy in Lung Cancer

Trial Year Antigen Type Notes Clinical Outcome Reference
Phase I/II ALVAC (n=3 lung, 15 gastrointestinal) 2000 CEA Non-replicating canarypoxvirus (ALVAC) constructed to express both human carcinoembryonic antigen (CEA) and the B7.1 co-stimulatory molecule SD in 3/18 [169]
Phase I (n=4 lung, 1 mesothelioma and 8 other) 2003 MUCI TG4010 is a viral suspension of a recombinant vaccinia vector (MVA) containing DNA sequences coding for the human MUC1 antigen and interleukin-2 (IL-2) SD in 4/13 [170]
Phase I (n=10 lung and 16 other) 2004 WT1 HLA-A*2402-restricted, natural, or modified 9-mer WT1 peptide emulsified with Montanide ISA51 SD in 2 and PR in 12 [171]
Phase I (n=19 NSCLC) 2004 Allogenic cell lines NSCLC modified to express B7.1 SD in 5 and PR in1 [122]
Phase II (n=171 NSCLC) 2005 MUCI MUCI peptide with liposome adjuvant Evidence of survival benefit [172]